Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E
Selinexor is an FDA approved selective inhibitor of the nuclear export protein exportin-1 (XPO1) and causes specific cancer cell death via nuclear accumulation of tumor suppressor proteins. Design of rational studies for the use of selinexor in combination with other therapeutic agents, such as immu...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Frontiers Media S.A.
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/3bc2ec99a6694182a242490b99350987 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|